Charles River Laboratories Reports 2025 Results and Provides 2026 Guidance

Details

reported a GAAP net loss of $276.6 million for Q4 2025 and $144.3 million for the full year, with non-GAAP earnings per share of $2.39 for Q4 and $10.28 for the full year. The company attributed the losses to significant non-cash intangible asset impairments and goodwill impairments. Charles River anticipates organic revenue growth and non-GAAP earnings per share increase in 2026, guided by positive demand trends and strategic initiatives.

Items reported

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. provides essential services to the pharmaceutical, biotechnology, and life sciences industries. The company specializes in preclinical and clinical lab services, offering clients a comprehensive suite of drug discovery and development services that expedite the process of getting new drugs and therapies to the market. Notably, Charles River's facilities offer expertise in the fields of oncology, immunology, and neuroscience, making it a critical partner for companies working in these therapeutic areas. The firm operates globally, enhancing its customers' ability to operate internationally through its wide network of laboratories and testing facilities. By enabling more efficient drug development cycles and reducing the time to market for new therapies, Charles River Laboratories plays a crucial role in the advancement of medical science and patient care worldwide. The company's commitment to high standards of animal welfare and ethical practices further underscores its reputation as a leader in quality and reliability within the research community.